Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 24418-86-8 Chemical Structure| 24418-86-8

Structure of SKI V
CAS No.: 24418-86-8

Chemical Structure| 24418-86-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis and has antitumor activity[1][2].

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SKI V

CAS No. :24418-86-8
Formula : C15H10O4
M.W : 254.24
SMILES Code : O=C1/C(OC2=CC=CC=C12)=C\C3=CC=C(O)C(O)=C3
English Name :2-(3,4-Dihydroxybenzylidene)benzofuran-3(2H)-one
MDL No. :MFCD07772193

Safety of SKI V

Related Pathways of SKI V

MAPK
PI3K-AKT

Isoform Comparison

Biological Activity

Description
SKI V is a highly potent noncompetitive inhibitor of non-lipid sphingosine kinase (SPHK; SK), with an IC50 of 2 μM for GST-hSK. Additionally, SKI V exhibits potent inhibition of PI3K, with an IC50 of 6 μM for hPI3K. It effectively reduces the formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V demonstrates apoptotic induction and displays significant antitumor activity[1][2].

In Vitro:

Cell Line
Concentration Treated Time Description References
PCCa-1 cells 1-30 µM 48-96 hours SKI-V inhibited pCCa-1 cell viability in a concentration- and time-dependent manner. Int J Biol Sci. 2022 Apr 18;18(7):2994-3005
C1 primary osteosarcoma cells 1-50 µM 48-96 hours SKI-V significantly inhibited survival, growth, proliferation, and migration of C1 primary osteosarcoma cells, and induced cell death and apoptosis Cell Death Discov. 2022 Feb 3;8(1):48

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Subcutaneous cervical cancer xenograft model Intraperitoneal injection 25 mg/kg Daily for 15 days SKI-V significantly inhibited the growth of subcutaneous pCCa-1 xenograft tumors. Int J Biol Sci. 2022 Apr 18;18(7):2994-3005
Nude mice Osteosarcoma xenograft model Intraperitoneal injection 30 mg/kg Once daily for 18 days SKI-V significantly suppressed the growth of osteosarcoma xenograft tumors, with SphK1 inhibition, ceramide increase, and Akt-mTOR inhibition detected in tumor tissues Cell Death Discov. 2022 Feb 3;8(1):48

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.93mL

0.79mL

0.39mL

19.67mL

3.93mL

1.97mL

39.33mL

7.87mL

3.93mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories